Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphoblastic leukemia (ALL). We developed a high-throughput sequencing method that universally amplifies antigen-receptor gene segments and identifies all clonal gene rearrangements (ie, leukemia-specific sequences) at diagnosis, allowing monitoring of disease progression and clonal evolution during therapy. In the present study, the assay specifically detected 1 leukemic cell among greater than 1 million leukocytes in spike-in experiments. We compared this method with the gold-standard MRD assays multiparameter flow cytometry and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) using diagnostic and follow-up samples from 106 patients with ALL. Sequencing detected MRD in all 28 samples shown to be positive by flow cytometry and in 35 of the 36 shown to be positive by ASO-PCR and revealed MRD in 10 and 3 additional samples that were negative by flow cytometry and ASO-PCR, respectively. We conclude that this new method allows monitoring of treatment response in ALL and other lymphoid malignancies with great sensitivity and precision. The www.clinicaltrials.gov identifier number for the Total XV study is NCT00137111.

[1]  V. Carlton,et al.  Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. , 2012, Blood.

[2]  David Wu,et al.  High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia , 2012, Science Translational Medicine.

[3]  James L. Zehnder,et al.  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment , 2011, Proceedings of the National Academy of Sciences.

[4]  J. V. van Dongen,et al.  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.

[5]  Asha B. Pillai,et al.  High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. , 2011, Blood.

[6]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Elaine Coustan-Smith,et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.

[8]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Dario Campana,et al.  Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[10]  D. Campana,et al.  Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.

[11]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[12]  R. Pieters,et al.  Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.

[13]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[14]  T. Barbui,et al.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.

[15]  A. Borkhardt,et al.  Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Fabbri,et al.  Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia , 2008, Leukemia.

[17]  S. Hunger,et al.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Haber,et al.  Mechanism of relapse in pediatric acute lymphoblastic leukemia , 2008, Cell cycle.

[19]  J. Gribben,et al.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. , 2007, Blood.

[20]  U. Kees,et al.  Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. , 2007, Blood.

[21]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[22]  M. Kneba,et al.  Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.

[23]  K. Rajewsky,et al.  Antibody repertoires generated by VH replacement and direct VH to JH joining. , 2006, Immunity.

[24]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[25]  D. Campana,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.

[26]  M. Cooper,et al.  The molecular basis and biological significance of VH replacement , 2004, Immunological reviews.

[27]  J. Gribben,et al.  Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. , 2003, Blood.

[28]  O. Haas,et al.  Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. , 2003, Blood.

[29]  M. van der Burg,et al.  Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. , 2002, Blood.

[30]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[31]  R. Rosenquist,et al.  Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor‐B acute lymphoblastic leukemia , 1999, European journal of haematology.

[32]  D. Hoelzer,et al.  Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.

[33]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[34]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[35]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[36]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[37]  S. Greenberg,et al.  Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements. , 1996, Blood.

[38]  C. E. van der Schoot,et al.  Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. , 1993, Blood.

[39]  G. Kitchingman.  Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. , 1993, Blood.

[40]  J. Salk.  Clonal evolution in cancer , 2010 .

[41]  R. Arceci,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .

[42]  C. V. D. Schoot,et al.  Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy , 2001, Leukemia.